Ibrutinib intermediate compounds, preparation methods and uses thereof

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 10023542
APP PUB NO 20170137386A1
SERIAL NO

15321750

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention relates to the technical field of ibrutinib, particularly to the technical field of ibrutinib intermediate compounds and preparation methods thereof. The intermediate compounds are represented by formula A, wherein, the dotted line represents a double bond or a single bond between carbon and oxygen.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
ZHEJIANG JIUZHOU PHARMACEUTICALS CO LTDTAIZHOU ZHENJIANG

International Classification(s)

  • [Classification Symbol]
  • [Patents Count]

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Che, Daqing Taizhou, CN 29 96
Gao, Hongjun Taizhou, CN 14 12
Hua, Yunyu Taizhou, CN 1 1
Li, Yuanqiang Taizhou, CN 18 79
Zhang, Xianyi Taizhou, CN 7 3

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Jan 17, 2026
11.5 Year Payment $7400.00 $3700.00 $1850.00 Jan 17, 2030
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00